Drugs that contain Lurasidone Hydrochloride
1. List of Latuda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE45573 | SUNOVION PHARMS INC | Process for producing imide compound |
Jun, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174975 | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Feb, 2024
(8 months from now) | |
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(8 months from now) | |
|
US9174975 (Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(1 year, 2 months from now) | |
|
USRE45573 (Pediatric) | SUNOVION PHARMS INC | Process for producing imide compound |
Dec, 2025
(2 years from now) | |
| US8883794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US9907794 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| US8729085 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
|
US9907794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
|
US8883794 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
|
US8729085 (Pediatric) | SUNOVION PHARMS INC | Pharmaceutical composition |
Nov, 2026
(3 years from now) | |
| US9827242 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(7 years from now) | |
| US9259423 | SUNOVION PHARMS INC | Method of treatment for mental disorders |
May, 2031
(7 years from now) | |
|
US9259423 (Pediatric) | SUNOVION PHARMS INC | Method of treatment for mental disorders |
Nov, 2031
(8 years from now) | |
Market Authorisation Date: 28 October, 2010
Treatment: Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia; Treatment of major depressive episodes associated with bipolar i disorder; Treatment of ...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic